FDA Approves ATOVAQUONE — Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals Inc. secured FDA approval for generic atovaquone, enabling the firm to compete in the established antiparasitic market. This approval broadens Glenmark's portfolio and creates a direct alternative to branded oral treatments, potentially increasing market share and revenue opportunities.